Table 1.
Patient characteristics, distribution, and total RNA preparation method
| Sample | Diagnosis | Blast cells (%) | Gold standard classification | Age (m-y) | RNA preparation method | Microarrays |
| #1 | Pre-pre-B-ALL | 95 | t(4;11) | 6 m | A,B,C | 3 |
| #2 | c-ALL | 70 | t(9;22) | 14 y | A,B,C | 3 |
| #3 | Early-T-ALL | 83 | negative | 16 y | A,B,C | 3 |
| #4 | c-ALL | 90 | t(12;21) | 13 y | A,B,C | 3 |
| #5 | Pre-B-ALL | 98 | t(1;19) | 10 y | A,B,C | 3 |
| #6 | c-ALL | 87 | hyperdiploid (DI = 1,233) | 2 y | A,B,C | 3 |
| #7 | c-ALL | 93 | negative | 16 y | A,B,C | 3 |
| #8 | AML | 89 | negative* | 16 y | A,B,C | 3 |
| #9 | c-ALL/Pro-B | 85 | t(9;22) | 5 y | A,B,C | 3 |
| #10 | Early-T-ALL | 94 | negative | 4 y | A,B,C | 3 |
| #11 | c-ALL | 88 | t(12;21) | 2 y | A,B,C | 3 |
| #12 | prepreB/c-ALL | 96 | Hyperdiploid (DI = 1,244) | 11 y | A,B,C | 3 |
| #13 | c-ALL | 95 | negative | 3 y | A,B,C | 3 |
| #14 | Pre-B-ALL | 87 | negative | 12 y | A,B,C | 3 |
| #15 | c-ALL | 94 | t(12;21) | 8 y | A,B,C | 3 |
| #16 | AML | 93 | t(9;11) | 6 y | A,B,C | 3 |
| #17 | Early-T-ALL | 87 | negative | 9 y | A,B,C | 3 |
| #18 | Early-T-ALL | 93 | negative | 9 y | A,B,C | 3 |
| #19 | c-ALL | 93 | hyperdiploid (DI = 1,160) | 2 y | A,B,C | 3 |
| #20 | prepreB/c-ALL | 85 | negative | 3 y | A,B,C | 3 |
| #21 | mature T-ALL | 94 | negative | 4 y | A,B,C | 3 |
| #22 | Pre-B-ALL | 95 | negative | 7 y | A,B,C | 3 |
| #23 | prepreB/c-ALL | 94 | negative | 4 y | A,B,C | 3 |
| #24 | c-ALL | 86 | negative | 5 y | A,B,C | 3 |
| TOTAL | 72 | |||||
| #25 | AML | 89 | negative** | 4 y | A,A,A,B,B,B,C,C,C | 9 |
| #26 | AML | 77 | t(1;11) | 6 m | A,A,A,B,B,B,C,C,C | 9 |
| #27 | prepreB/CALL | 92 | negative | 4 y | A,A,A,B,B,B,C,C,C | 9 |
| TOTAL (replicates) | 27 | |||||
| TOTAL in Study | 99 | |||||
Negative = negative for all gold standard tests regarding recurrent translocations. Age at diagnosis is expressed as months (m) or years (y). Method A: QIAshredder homogenization using a biopolymer shredding system in a microcentrifuge spin-column format followed by RNeasy purification; Method B: TRIzol RNA isolation. Method C: TRIzol RNA isolation followed by RNeasy purification. Samples #1–24 have been extracted in triplicates; Samples #25, #26, and #27 have been extracted in multiple technical replicates (n = 3). (*) Karyotype information: 46, XY; (**) Karyotype information: 46, XY der(9p) [3]/46, XY [19].